The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

W. Sledge, George; Toi, Masakazu; Neven, Patrick; Sohn, Joohyuk; Inoue, Kenichi; Pivot, Xavier; Burdaeva, Olga; Okera, Meena; Masuda, Norikazu; A. Kaufman, Peter; Koh, Han; Grischke, Eva‐Maria; Conte, PierFranco; Lu, Yi; Barriga, Susana; Hurt, Karla; Frenzel, Martin; Johnston, Stephen; Llombart‐Cussac, Antonio

doi:10.1001/jamaoncol.2019.4782

Public

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

Published in JAMA Oncology • Sep 29, 2019

Authors:

George W. Sledge

Masakazu Toi

Patrick Neven

Abstract

IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (...

Subject

Fulvestrant

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!